Propanc Biopharma (PPCB) announced a plan to acquire $100M of Ethereum (ETH-USD) over the next 12 months. The asset purchase of Ethereum will enhance a multi-faceted corporate strategy of cryptocurrency exposure, pharmaceutical drug development and asset acquisition within the Company’s key focus area of biotechnology to improve human health and society.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PPCB: